perifosine

Related by string. Perifosine * * perifosine KRX . Perifosine KRX . perifosine novel potentially . compound perifosine . + Perifosine Evaluation *

Related by context. All words. (Click for frequent words.) 75 Perifosine 72 carfilzomib 70 FOLOTYN 70 PXD# 70 ganetespib 70 XL# [003] 69 AP# [003] 69 Marqibo 69 satraplatin 69 ofatumumab 69 aflibercept 68 MGCD# [001] 68 alvespimycin 68 picoplatin 68 sapacitabine 68 Phase Ib 68 axitinib 68 obatoclax 67 INCB# [001] 67 celgosivir 67 enzastaurin 67 tanespimycin 67 pralatrexate 67 rNAPc2 67 ixabepilone 67 HGS ETR1 67 voreloxin 67 OXi# 67 ASA# 67 CoFactor 67 glufosfamide 67 Amrubicin 67 relapsed multiple myeloma 66 Phenoptin 66 PF # [001] 66 TREANDA 66 pomalidomide 66 blinatumomab 66 Vectibix 66 refractory multiple myeloma 66 amrubicin 66 panitumumab 66 T DM1 66 pertuzumab 66 lintuzumab 66 elacytarabine 66 HuMax CD4 66 Targretin 66 tamibarotene 66 IMGN# 65 cilengitide 65 Cloretazine R VNP#M 65 clofarabine 65 Bortezomib 65 INCB# [002] 65 phase IIb clinical 65 ADVEXIN 65 nitazoxanide 65 nimotuzumab 65 Amigal 65 brentuximab vedotin 65 HER2 positive metastatic breast 65 RDEA# 65 eniluracil 65 Satraplatin 65 belinostat 65 RG# [001] 65 OncoVEX GM CSF 65 relapsed refractory multiple myeloma 64 metastatic renal cell carcinoma 64 Aplidin 64 hematological malignancies 64 Phase 1b 64 AEZS 64 investigational compound 64 forodesine 64 Panzem R NCD 64 ZYBRESTAT 64 seliciclib 64 decitabine 64 dacetuzumab 64 VELCADE 64 BCX# 64 eltrombopag 64 talactoferrin 64 atacicept 64 CYT# 64 bevacizumab Avastin 64 ELACYT 64 Virulizin R 64 Azixa 64 vidofludimus 64 PEG Interferon lambda 64 Tamibarotene 64 teduglutide 64 TELCYTA 64 ISIS # 64 Genasense 64 Imprime PGG 64 ridaforolimus 64 Tarceva TM 64 mapatumumab 64 Æterna Zentaris 63 Treanda 63 ERBITUX 63 Bezielle 63 SUTENT 63 adecatumumab 63 temozolomide 63 Clolar 63 bortezomib 63 BiovaxID 63 capecitabine Xeloda R 63 tesmilifene 63 JAK inhibitor 63 sorafenib 63 thymalfasin 63 FTY# 63 Ceflatonin 63 anticancer agent 63 radiation sensitizer 63 XmAb# 63 HGS# 63 anti leukemic 63 CYC# 63 bendamustine 63 tivozanib 63 valopicitabine 63 MGCD# [002] 63 Zerenex 63 HuMax EGFr 63 BAY #-# 63 sunitinib malate 63 sunitinib 63 metastatic colorectal cancer 63 Nexavar ® 63 eculizumab 63 Dacogen injection 63 registrational trial 63 monotherapy 63 Virulizin ® 63 KRN# 63 AEGR 63 Fludara 63 Taxotere ® 63 deforolimus 62 Xcytrin 62 CA4P 62 PI3K/Akt pathway inhibitor 62 Alpharadin 62 MOZOBIL 62 Irinotecan 62 nab paclitaxel 62 HRPC 62 PEG SN# 62 Phase Ib II 62 Phase 2a trial 62 neratinib 62 HDAC inhibitor 62 Carfilzomib 62 ocrelizumab 62 torezolid phosphate 62 Defibrotide 62 AEG# 62 IMC A# 62 tesetaxel 62 EOquin TM 62 veltuzumab 62 afatinib 62 Aflibercept 62 rituximab 62 teriflunomide 62 Cloretazine ® 62 oral ridaforolimus 62 APOPTONE 62 elotuzumab 62 YONDELIS 62 vascular disrupting agent 62 Cloretazine 62 romidepsin 62 Cotara 62 registrational 62 Reolysin 62 Herceptin trastuzumab 62 HspE7 62 dirucotide 62 bevacizumab 62 phase IIb 62 telaprevir 62 mertansine 62 Actemra 62 Cloretazine R 62 GRN#L 62 OPAXIO 62 Tarceva 62 galiximab 62 dasatinib 62 LymphoStat B 62 ABRAXANE 62 dose escalation trial 62 sorafenib tablets 62 Taxotere R 62 omacetaxine 62 docetaxel 62 Nexavar 62 albinterferon alfa 2b 62 metaglidasen 62 pivotal Phase III 62 ASONEP 62 Phase 2b trial 62 vinorelbine 62 bevacizumab Avastin ® 62 gemcitabine 62 Phase 1b clinical 62 cetuximab Erbitux 62 daclizumab 62 Vidaza 61 Debio 61 Avastin bevacizumab 61 EndoTAG TM -1 61 lapatinib 61 Phase III clinical 61 refractory PTCL 61 Serdaxin 61 ceftaroline 61 bavituximab 61 INC# 61 B CLL 61 otelixizumab 61 palifosfamide 61 imetelstat 61 azacitidine 61 Azedra 61 Archexin 61 fidaxomicin 61 erlotinib 61 FOLOTYN ® 61 DAVANAT R 61 NSCLC 61 ProLindac 61 elesclomol 61 docetaxel chemotherapy 61 antitumor activity 61 Ceplene 61 REVLIMID 61 Phase Ib study 61 Traficet EN 61 Dacogen 61 proteasome inhibitor 61 Amplimexon 61 targeting CD# 61 BiTE antibody 61 laquinimod 61 PROSTVAC TM 61 sorafenib Nexavar ® 61 carboplatin paclitaxel 61 Gemzar ® 61 ponatinib 61 GATTEX 61 MEK inhibitor 61 mipomersen 61 IMA# 61 Phase Ib clinical 61 Onrigin 61 Civacir 61 Doxil 61 ZACTIMA 61 TORISEL 61 ipilimumab 61 heavily pretreated 61 HGS ETR2 61 Annamycin 61 BIBW 61 Phase 1b trial 61 perifosine KRX 61 Restanza 61 lumiliximab 61 CR# vcMMAE 61 Clevudine 61 EGFR expressing mCRC 61 FOLFIRI 61 oral antiviral 61 Bevacizumab 61 Triolex 61 vandetanib 61 ozarelix 61 pradefovir 61 L MTP PE 61 HuMax CD# 61 dose escalation 61 mRCC 61 PROMACTA 61 phase Ib 61 ENMD 61 SCH # 61 histone deacetylase HDAC inhibitor 61 vilazodone 61 pemetrexed 61 OvaRex ® MAb 60 clevudine 60 ThermoDox 60 Phase IIb 60 phase IIa clinical 60 Pralatrexate 60 Proxinium TM 60 MEK inhibitors 60 Panzem 60 crizotinib PF # 60 Allovectin 7 60 mCRC 60 ILLUMINATE 60 TYKERB 60 Tarceva erlotinib 60 VEGF Trap 60 vemurafenib 60 Phase #b/#a 60 Allovectin 7 ® 60 taxane 60 pixantrone 60 Erbitux 60 refractory chronic lymphocytic 60 custirsen 60 entinostat 60 PLX# 60 AVN# [001] 60 PS# [001] 60 castration resistant prostate cancer 60 Omacetaxine 60 relapsed SCLC 60 Jevtana 60 bafetinib 60 ZEVALIN 60 Increlex ® 60 TOCOSOL Paclitaxel 60 Xanafide 60 ularitide 60 phase 2a 60 EOquin 60 Akt inhibitor 60 Epratuzumab 60 trastuzumab DM1 T DM1 60 panitumumab Vectibix 60 cediranib 60 Alzhemed TM 60 tocilizumab 60 humanized anti 60 Phase 2b clinical 60 trastuzumab 60 TELINTRA 60 L BLP# 60 SNT MC# 60 Mipomersen 60 resistant ovarian cancer 60 Panzem R 60 Troxatyl 60 APD# 60 Symadex 60 sorafenib Nexavar 60 XYOTAX 60 Plicera 60 ELND# 60 PANVAC VF 60 Triapine R 60 Hsp# inhibitor 60 Phase III 60 zanolimumab 60 Doxil ® 60 ProSavin 60 Fx #A 60 anti TNF 60 CD# antibody [001] 60 cinacalcet HCl 60 CBLC# 60 Velcade bortezomib 60 HuLuc# 60 REOLYSIN ® 60 dimebon 60 MyVax R 60 Phase IIb clinical 60 CIMZIA TM 60 MDV# 60 Evoltra ® 60 LUX Lung 60 nilotinib 60 ATL/TV# 60 rindopepimut 60 Phase IIa clinical 60 Telaprevir 60 Phase IIa trial 60 carboplatin 60 hormone refractory prostate cancer 60 PSN# [002] 60 TRISENOX 60 SCCHN 60 talabostat 60 ON #.Na 60 VIDAZA 60 immunomodulatory 60 HQK 60 Revlimid 60 vosaroxin 60 gefitinib 60 AQ4N 60 erlotinib Tarceva ® 60 telbivudine 60 gefitinib Iressa 59 Allovectin 7 R 59 hematologic malignancies 59 Ceflatonin R 59 bortezomib Velcade R 59 PEG PAL 59 preclinical studies 59 Glufosfamide 59 trabedersen 59 lixisenatide 59 Blinatumomab 59 PSMA ADC 59 Campath 59 CTAP# Capsules 59 MAGE A3 ASCI 59 Zolinza 59 iniparib 59 preclinical 59 PLK1 SNALP 59 ONCONASE 59 investigational drug 59 NVA# 59 Phase 2b 59 brentuximab vedotin SGN 59 PEG INTRON 59 mTOR inhibitor 59 Bicifadine 59 epothilone 59 apaziquone 59 AZILECT R 59 Rituxan rituximab 59 farletuzumab 59 refractory gout 59 refractory Hodgkin lymphoma 59 Laquinimod 59 plus dexamethasone 59 ATL# [001] 59 EFAPROXYN 59 Vilazodone 59 voclosporin 59 Phase 2b study 59 epigenetic therapies 59 LY# [003] 59 metastatic HRPC 59 platinum refractory 59 oral prodrug 59 dose escalation Phase 59 IRX 2 59 brostallicin 59 ongoing Phase 1b 59 NGX# 59 Prochymal 59 JAK1 59 relapsed ovarian cancer 59 Advexin 59 initiate Phase 1b 59 Tyrima 59 peginesatide 59 temsirolimus 59 Hematide 59 PDX pralatrexate 59 Dapagliflozin 59 ZD# [001] 59 metastatic melanoma 59 PNP inhibitor 59 Phenserine 59 CUDC 59 Abiraterone acetate 59 ThermoDox R 59 Randomized Phase 59 viral kinetics 59 Tavocept 59 EndoTAGTM 1 59 PCK# 59 NXL# 59 Belinostat 59 CCX# 59 ThermoDox ® 59 Alocrest 59 selective androgen receptor modulator 59 Revlimid lenalidomide 59 Tesetaxel 59 capecitabine 59 imatinib Gleevec ® 59 IAP inhibitors 59 hematological cancers 59 Viramidine 59 R#/MEM # 59 seliciclib CYC# 59 Rexin G 59 Phase IIIb clinical 59 DOXIL 59 Vandetanib 59 aflibercept VEGF Trap 59 Onconase 59 cetuximab Erbitux ® 59 cetuximab 59 ANA# 59 zalutumumab 59 Rituxan 59 randomized Phase 59 Ixempra 59 Phase 2a clinical 59 virus HCV protease inhibitor 59 TACI Ig 59 BEXXAR 59 imatinib Gleevec 59 RGB # 59 fipamezole 59 Ambrisentan 59 ruxolitinib 59 ISENTRESS 59 MAP# 59 abiraterone acetate 59 XYOTAX TM 59 refractory metastatic colorectal cancer 59 Onco TCS 59 Phase IIa trials 59 dose escalation clinical 59 Neuradiab 59 IDX# 59 epratuzumab 59 bazedoxifene 59 Nexavar sorafenib 59 Folotyn 59 Velcade 59 elvitegravir 59 mCRC patients 59 TYSABRI 59 maribavir 59 CIMZIA ™ 59 solid tumors 59 Aptivus ® 59 Apaziquone 59 depsipeptide 59 FOLFIRI chemotherapy 59 Targeted Chemotherapy 59 Pirfenidone 59 Viprinex 59 Avastin 58 Afinitor 58 FavId 58 Atiprimod 58 metastatic CRC 58 iSONEP 58 Sym# 58 DB# [003] 58 Chemophase 58 Intravenous CP 58 TG# [001] 58 OMAPRO 58 IIa trial 58 Genasense ® 58 HCD# [002] 58 TKM ApoB 58 recurrent glioblastoma 58 BENLYSTA 58 methylnaltrexone 58 metastatic hormone refractory 58 huC# DM4 58 Locteron 58 oral anticancer 58 BZL# 58 fluoropyrimidine 58 Torisel 58 pazopanib 58 viral kinetic 58 darapladib 58 phase IIa 58 Icatibant 58 liposomal formulation 58 NKTR 58 PRTX 58 Trastuzumab 58 Phase IIa 58 vorinostat 58 HIV integrase inhibitor 58 MBP# [001] 58 pirfenidone 58 trabectedin 58 TYZEKA 58 romiplostim 58 metastatic castrate resistant 58 R sorafenib tablets 58 Abraxane 58 antibody MAb 58 PREOS 58 TroVax 58 AVASTIN 58 JANUVIA 58 Asentar 58 diabetic nephropathy 58 Neulasta ® 58 MAXY G# 58 TNFerade 58 relapsed refractory 58 BENLYSTA ® 58 DXL# 58 OHR/AVR# 58 refractory acute myeloid 58 Phase 2a 58 linaclotide 58 cangrelor 58 PROVENGE 58 DU #b 58 orBec R 58 XL# XL# 58 orally administered inhibitor 58 BRIM2 58 Pemetrexed 58 G CSF 58 investigational humanized monoclonal antibody 58 TEMODAL 58 gemcitabine chemotherapy 58 Dasatinib 58 multiple myeloma MM 58 bosutinib 58 Tarvacin 58 TRIOLEX 58 LibiGel ® 58 Fibrillex TM 58 recurrent ovarian cancer 58 Bronchitol 58 lenalidomide Revlimid R 58 refractory CLL 58 Apoptone 58 Golimumab 58 Phase Ib clinical trials 58 anticancer therapies 58 alvimopan 58 angiogenesis inhibitor 58 topotecan 58 Pazopanib 58 Clolar ® 58 ACTEMRA 58 Romidepsin 58 oritavancin 58 Elagolix 58 goserelin 58 Vectibix panitumumab 58 #ME# 58 receptor tyrosine kinase inhibitor 58 Copegus ribavirin 58 PKC# 58 thalidomide Thalomid 58 anticancer compound 58 irinotecan 58 pitavastatin 58 OncoVEX 58 MT# MEDI 58 erlotinib Tarceva 58 investigational 58 MEK inhibitor RDEA# 58 relapsing multiple sclerosis 58 CCR5 antagonist 58 UPLYSO 58 Pivotal Phase III 58 cetuximab Erbitux R 58 fostamatinib 58 OvaRex R 58 plus gemcitabine 58 oral proteasome inhibitor 58 Voreloxin 58 cutaneous T cell 58 Cethrin 58 TRO# 58 CD# monoclonal antibody 58 dasatinib Sprycel ® 58 AFREZZA 58 polymerase inhibitor 58 Phase IIb trial 58 antithrombotic 58 M Vax 58 antiviral activity 58 Aplidin R 58 Orazol 58 IMP# 58 Catena ® 58 SAR# [004] 58 advanced NSCLC 58 MYDICAR ® 58 EGFR inhibitors 58 lapatinib Tykerb 58 preclinically 58 Campath ® 58 dacarbazine 58 integrase inhibitor 58 velaglucerase alfa 58 Hedgehog Pathway Inhibitor 58 BRAF inhibitor 58 refractory APL 58 IRESSA 58 TBC# 58 Arranon 58 Anturol 58 metastatic castration resistant 58 RITUXAN 58 tezampanel 58 iclaprim 58 indolent NHL 58 refractory indolent non 57 ZADAXIN 57 hepatocellular carcinoma 57 trastuzumab DM1 57 Phase #b/#a trial 57 PRT# 57 oral Xeloda 57 KRAS wild 57 Tovaxin 57 GRN# 57 regorafenib 57 pivotal Phase 57 Aurora kinase 57 RP# [002] 57 LEUKINE 57 CBLB# 57 Xyotax 57 Behcet uveitis 57 pan HDAC inhibitor 57 Dalbavancin 57 Daclizumab 57 ThGRF 57 Insegia 57 MabCampath 57 Pixantrone 57 MLN# 57 INTELENCE 57 Cladribine Tablets 57 ataluren 57 imatinib 57 mifamurtide 57 anti EGFR antibody 57 melphalan prednisone 57 dose escalation study 57 standard chemotherapy regimen 57 Targretin capsules 57 HCV protease inhibitor 57 maximally tolerated dose 57 Exelixis XL# 57 CCX# B 57 gemcitabine Gemzar ® 57 Telcyta 57 milatuzumab 57 tolerability 57 DR Cysteamine 57 riociguat 57 OMP #M# 57 anti TNF alpha 57 ofatumumab HuMax CD# 57 Evoltra TM 57 SABCS 57 Factor VIIa 57 adecatumumab MT# 57 GVAX 57 vascular disrupting agents 57 sulodexide 57 masitinib 57 TASQ 57 KNS # 57 NEBIDO 57 somatostatin analogue 57 lorvotuzumab mertansine 57 FOLFOX 57 anti VEGF 57 TH# [003] 57 Tanespimycin 57 Vicinium TM 57 taxanes 57 BR.# 57 eprotirome 57 posaconazole 57 chronic lymphocytic leukemia CLL 57 raltegravir 57 lubiprostone 57 capecitabine Xeloda 57 Stedivaze 57 Corlux 57 VPRIV 57 ZYBRESTAT fosbretabulin 57 novel anticancer 57 Ceflatonin ® 57 Omnitarg 57 Panitumumab 57 disease modifying 57 tyrosine kinase inhibitor 57 Navelbine ® 57 ZOLINZA 57 GALNS 57 XL# XL# XL# 57 BrachySil TM 57 Revimmune 57 humanized monoclonal antibody 57 TTF Therapy 57 rALLy trial 57 BioNumerik 57 Oncophage 57 ONTAK 57 LEP ETU 57 Ozarelix 57 brivaracetam 57 randomized Phase III 57 proteasome inhibitor bortezomib 57 biologic therapy 57 Quinamed 57 pegloticase 57 cetrorelix 57 microtubule targeting 57 CD3 monoclonal antibody 57 INGN 57 docetaxel Taxotere R 57 SinuNase 57 Erbitux cetuximab 57 CLORETAZINE TM VNP#M 57 ambrisentan 57 midstage clinical 57 tecarfarin 57 ospemifene 57 Urocidin 57 cell lymphoma CTCL 57 Gemcitabine 57 tremelimumab 57 MGd 57 Androxal 57 refractory CTCL 57 TMC# [002] 57 febuxostat 57 PREZISTA r 57 Nanobody 57 trastuzumab Herceptin R 57 ENMD # 57 YONDELIS R 57 orally bioavailable 57 protease inhibitor 57 paclitaxel Taxol ® 57 leukemia CLL 57 Telatinib 57 LymphoStat B TM 57 STELARA 57 anticancer therapy 57 Leukine 57 DAVANAT 57 Guanilib 57 limiting toxicity 57 dose cohorts 57 Hsp# Inhibitor 57 ALN VSP 57 TMC# [001] 57 abiraterone 57 investigational monoclonal antibody 57 IL# PE#QQR 57 atrasentan 57 resminostat 57 pegylated liposomal doxorubicin 57 multiple ascending dose 57 Combidex 57 Phase III pivotal 57 Fodosine 57 Eltrombopag 57 Rebif ® 57 Alemtuzumab 57 Teysuno 57 dasatinib Sprycel 57 BARACLUDE R 57 phenoxodiol 57 regadenoson 57 tosedostat 57 Nuvion 57 nucleoside 57 pegylated interferon alpha 57 UVIDEM 57 EGFR targeting 57 alemtuzumab Campath 57 olaparib 57 relapsing remitting multiple sclerosis 57 ® natalizumab 57 relapsed myeloma 57 Hodgkin lymphoma NHL 57 samalizumab 57 placebo controlled Phase 57 alogliptin 57 antiplatelet agent 57 Orphan Drug designations 57 evaluating Xcytrin 57 RhuDex ® 57 AZD# 57 hepatocellular cancer 57 Azilect ® 57 Menerba 57 ispinesib 57 bortezomib Velcade 57 visilizumab 57 oxidative stress inducer 57 favorable tolerability 57 Erlotinib 57 FOLFOX6 chemotherapy regimen 57 Santhera 57 VNP#M 57 mycophenolate mofetil 57 VELCADE melphalan 57 Xeloda 57 pediatric malignancies 56 pharmacodynamic 56 rALLy clinical trial 56 PHX# 56 ONX 56 pediatric acute lymphoblastic 56 KRAS status 56 Phase III randomized controlled 56 incyclinide 56 Stimuvax 56 midstage trials 56 evaluating tivozanib 56 novel VDA molecule 56 boosted protease inhibitor 56 Nasulin 56 PDE4 inhibitor 56 SPRYCEL ® 56 #I TM# 56 ITMN 56 Elesclomol 56 Campath alemtuzumab 56 DCVax R Brain 56 selective kinase inhibitor 56 CK # 56 tipifarnib 56 atrial fibrillation budiodarone ATI 56 pramlintide 56 radezolid 56 TASKi2 56 palonosetron 56 LymphoStat B belimumab 56 fingolimod 56 Diamyd ® 56 COMFORT II 56 Fludara ® 56 Vasovist 56 StemEx R 56 oral rivaroxaban 56 Elotuzumab 56 baminercept 56 S/GSK# 56 ORENCIA ® 56 heavily pretreated patients 56 cancer neuroendocrine tumor 56 INT# [002] 56 VAPRISOL 56 AMD# [003] 56 HCV SPRINT 56 lesinurad 56 clinical trial 56 pegfilgrastim 56 Cimzia ® 56 DPP4 inhibitor 56 immunomodulator 56 Prestara 56 omecamtiv mecarbil 56 follicular NHL 56 Phase #/#a trial 56 daptomycin 56 rilonacept 56 JAK inhibitors 56 BNC# 56 etanercept 56 molecularly targeted 56 isoform selective 56 YERVOY 56 docetaxel Taxotere 56 ATryn R 56 rituximab Rituxan 56 bortezomib Velcade ® 56 sorafenib Nexavar R 56 volociximab 56 Betaferon ® 56 Increlex R 56 pharmacokinetic 56 anidulafungin 56 APF# 56 systemic ALCL 56 Desmoteplase 56 insulin sensitizing 56 Raptiva ® 56 leading oral taxane 56 RECOTHROM 56 Xeloda ® 56 brain metastases 56 phase IIb trial 56 multi kinase inhibitor 56 systemically administered 56 LEVADEX 56 nonclinical studies 56 gallium containing 56 ANG# 56 XL# XL# XL# XL# 56 Picoplatin

Back to home page